Red Flags Detected

  • Material Weakness (new) — Management identified multiple material weaknesses in internal control over financial reporting as of March 31, 2026, including documentation gaps, segregation of duties issues, insufficient review controls, and ineffective IT access controls.
NASDAQ: LABT Lakewood-Amedex Biotherapeutics Inc. 10-Q

LABT discloses material control weaknesses, $11.7K cash at quarter-end, $6.8M emergency raise

Filed May 22, 2026 · Period ending March 31, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade LABT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 24, 2026 4:35 AM